Showing 601-610 of 9273 results for "".
Protecting Assets in a Divorce
https://practicaldermatology.com/topics/practice-management/protecting-assets-in-a-divorce/18771/Statistics show that half of marriages end in divorce. Financial consequences can be significant. OJM Group principal David Mandell, JD, MBA, discusses how physicians can protect their assets in the pre-marital and the marital stages in the event of a divorce. Always contact local counsel before taThe Benjamin Button Effect: Noninvasive Rejuvenation
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-benjamin-button-effect-noninvasive-rejuvenation/18813/Heidi Waldorf, MD explains her approach to helping patients achieve the best, most natural results from noninvasive rejuvenation. She says her patients want to look like themselves after aesthetic treatment—but a healthier, more youthful version of themselves. Dr. Waldorf shares tips for interactingChemoprevention Strategies for AK Patients
https://practicaldermatology.com/topics/skin-cancer-photoprotection/chemoprevention-strategies-for-ak-patients/18822/Neal Bhatia, MD, Chief Medical Editor of Practical Dermatology®, provides strategies for treating actinic keratoses, as well as for prevention and management. He discusses the importance of sun protection and photodamage prevention, and says the key to treatment and maintenance is combination therapPediatric Atopic Dermatitis And Psoriasis
https://practicaldermatology.com/topics/psoriasis/pediatric-atopic-dermatitis-and-psoriasis/18631/Lawrence Eichenfield, MD provides an update on pediatric atopic dermatitis and psoriasis. Unfortunately, he said, many children remain undertreated for their eczema despite the availability of effective treatments and a number of topical and systemic products on the horizon. Dr. Eichenfield also proValeant Acquires Salix; Actavis Changing Name
https://practicaldermatology.com/series/dermwire-tv/valeant-acquires-salix-actavis-changing-name/18963/Valeant expands its portfolio with the acquisition of GI market leader Salix. Actavis divests Doryx and considers a name change to Allergan. Kythera acquires rights for investigational hair therapies. And Cynosure's 532nm laser delivery system is FDA cleared for PicoSure.Otezla Approved for Plaque Psoriasis
https://practicaldermatology.com/topics/psoriasis/dermiretv-otezla-approved-for-plaque-psoriasis/19031/In this week's edition of DermWireTV from the publishers of Practical Dermatology® magazine and DermWire.com, a look at Celgene's Otezla for psoriasis--the first PDE4 inhibitor approved for plaque psoriasis. Plus, Ranbaxy's new dosage strengths of Absorica (isotretinoin), and Galderma's search for pSecrets of Effective Communication
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/secrets-of-effective-communication/19085/Heidi Waldorf, MD, FAAD and Steven Dayan, MD, FACS, Co-Chief Medical Editors of Modern Aesthetics®magazine, share strategies for understanding patient needs, setting expectations, and building relationships.Update on Topical Acne Therapy for Adult Women
https://practicaldermatology.com/topics/general-topics/update-on-topical-acne-therapy-for-adult-women/19166/Diane Berson, MD, FAAD discusses the approach to management of acne in the adult female patient, emphasizing the role of vehicle to affect the patient experience, promote adherence, and optimize outcomes. Bonus Material: Hormonal Therapy for Female Acne Bonus Material: Procedures for Adult Female ADr. Goldberg Discusses Experience with the VariLite Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-goldberg-discusses-experience-with-gemini-laser/19468/“One of the great things about being in the laser field is there are new lasers that come out every day. It makes it a very exciting arena to be in. The problem is the popular machine of today, unfortunately, often becomes the machine that you don't need a year from now. The VariLite is tried andOrigins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).